Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODYSSEY OPTIONS I
NCT01730040Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2012
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of alirocumab in hypercholesterolemia (7 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Percent Change From Baseline in Calculated LDL-C at 24 weeks. Started Oct 2012; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT01730040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01730040.